Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-PD-1 Therapy Combined With Systemic Chemotherapy and Intraperitoneal Nab-paclitaxel as First-line Treatment for Advanced Gastric Cancer With Malignant Ascites: An Exploratory Study of Efficacy and Predictive Biomarkers

NCT07855640 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT07855640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07855640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-PD-1 Therapy Combined With Systemic Chemotherapy and Intraperitoneal Nab-paclitaxel as First-line Treatment for Advanced Gastric Cancer With Malignant Ascites: An Exploratory Study of Efficacy and Predictive Biomarkers
Lead sponsor
Zhejiang Cancer Hospital
Phase
Observational
Overall status
Recruiting
Start date
July 1, 2026
Completion date
July 31, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ascites, malignant, gastric cancer (gc), gastric cancer peritoneal metastases